Cargando…
Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929005/ https://www.ncbi.nlm.nih.gov/pubmed/36094634 http://dx.doi.org/10.1007/s41669-022-00366-y |
| _version_ | 1784888754319654912 |
|---|---|
| author | Felizzi, F. Launonen, Aino Thuresson, P.-O. |
| author_facet | Felizzi, F. Launonen, Aino Thuresson, P.-O. |
| author_sort | Felizzi, F. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9929005 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99290052023-02-16 Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial Felizzi, F. Launonen, Aino Thuresson, P.-O. Pharmacoecon Open Correction Springer International Publishing 2022-09-12 /pmc/articles/PMC9929005/ /pubmed/36094634 http://dx.doi.org/10.1007/s41669-022-00366-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correction Felizzi, F. Launonen, Aino Thuresson, P.-O. Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial |
| title | Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial |
| title_full | Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial |
| title_fullStr | Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial |
| title_full_unstemmed | Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial |
| title_short | Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial |
| title_sort | correction to: approximation of long-term survival with polatuzumab vedotin plus bendamustine and rituximab for patients with relapsed/refractory diffuse large b-cell lymphoma: results based on the go29365 trial |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929005/ https://www.ncbi.nlm.nih.gov/pubmed/36094634 http://dx.doi.org/10.1007/s41669-022-00366-y |
| work_keys_str_mv | AT felizzif correctiontoapproximationoflongtermsurvivalwithpolatuzumabvedotinplusbendamustineandrituximabforpatientswithrelapsedrefractorydiffuselargebcelllymphomaresultsbasedonthego29365trial AT launonenaino correctiontoapproximationoflongtermsurvivalwithpolatuzumabvedotinplusbendamustineandrituximabforpatientswithrelapsedrefractorydiffuselargebcelllymphomaresultsbasedonthego29365trial AT thuressonpo correctiontoapproximationoflongtermsurvivalwithpolatuzumabvedotinplusbendamustineandrituximabforpatientswithrelapsedrefractorydiffuselargebcelllymphomaresultsbasedonthego29365trial |